…
Curaleaf Holdings, Inc. engages in the retail and wholesale of cannabis products in the United States and internationally. The company operates licensed cultivation; and pharma-grade cannabis processing and manufacturing facilities. It also supplies cannabis on a wholesale basis to Australia, New Zealand, the United Kingdom and various European countries, including Germany, Italy, Poland, the Czech Republic, Switzerland, Sweden and Norway. In addition, the company operates a medical cannabis clinic and holds a pharmacy license. It serves the medical and adult-use cannabis markets through retail and wholesale channels. The company is based in Stamford, Connecticut.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Curaleaf Holdings Inc. is a U.S.-focused cannabis operator that cultivates, processes and dispenses medical and adult-use products across multiple states. Long-term growth drivers include expanding retail footprint, product diversification and potential state and federal policy changes that may increase legal market access. Investors may find the company attractive for its scale and broad geographic presence, which could support revenue growth as markets mature.
Key investment risks include persistent federal illegality and shifting state regulations, intense competition and pricing pressure, and execution risks around licensing, integration and margin stability.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -79.58M | -117.63M | -167.86M | -112.59M | -77.98M |
| Minority interest | -2.92M | - | - | - | - |
| Net income | -235.12M | -215.42M | -379.53M | -481.81M | -258.19M |
| Selling general administrative | 458.07M | 398.74M | 392.79M | 408.15M | 373.90M |
| Selling and marketing expenses | - | 48.48M | 41.99M | 39.75M | 41.84M |
| Gross profit | 498.20M | 639.25M | 644.70M | 667.70M | 607.67M |
| Reconciled depreciation | 216.04M | - | - | - | - |
| Ebit | 25.90M | -17.01M | 57.88M | 84.60M | 73.43M |
| Ebitda | 169.76M | 233.14M | 343.90M | 300.25M | 240.89M |
| Depreciation and amortization | 143.87M | 250.16M | 286.02M | 215.64M | 167.45M |
| Operating income | 25.90M | 20.20M | 57.88M | 84.60M | 73.43M |
| Other operating expenses | 1264.44M | 1322.61M | 1759.65M | 1575.81M | 1426.01M |
| Interest expense | 102.59M | 100.62M | 100.38M | 88.84M | 90.26M |
| Tax provision | 123.69M | 98.59M | - | - | - |
| Interest income | 0.66M | 93.22M | - | - | - |
| Net interest income | -100.17M | - | - | - | - |
| Extraordinary items | - | -5.79M | - | - | - |
| Income tax expense | 125.85M | 98.59M | 154.66M | 232.80M | 191.13M |
| Total revenue | 1290.33M | 1342.80M | 1817.53M | 1660.41M | 1499.45M |
| Total operating expenses | 472.30M | 619.05M | 586.82M | 583.10M | 534.24M |
| Cost of revenue | 792.14M | 703.55M | 1172.83M | 992.71M | 891.78M |
| Total other income expense net | -105.48M | -137.83M | -225.73M | -197.20M | -151.41M |
| Net income from continuing ops | -244.20M | - | - | - | - |
| Net income applicable to common shares | - | -215.42M | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 2840.14M | 2949.54M | 4083.15M | 4626.56M | 3922.17M |
| Intangible assets | 1009.27M | 1085.40M | 1172.44M | 1213.30M | 1010.01M |
| Other current assets | 265.60M | 7.19M | 63.55M | 283.57M | 147.04M |
| Total liab | 2001.39M | 2088.32M | 2538.68M | 2728.52M | 1818.91M |
| Total stockholder equity | 754.97M | 861.21M | 1385.38M | 1733.94M | 1952.98M |
| Other current liab | 151.94M | - | 452.51M | 451.79M | 160.26M |
| Common stock | - | 2237.47M | - | - | 2811.70M |
| Capital stock | 0.00M | - | - | - | - |
| Retained earnings | -1584.36M | -1356.17M | -1504.19M | -1164.65M | -618.26M |
| Good will | 633.96M | 628.88M | 826.27M | 847.02M | 765.26M |
| Other assets | - | 0.40M | 0.00M | 0.00M | - |
| Cash | 101.39M | - | 121.07M | 221.10M | 378.10M |
| Cash and equivalents | - | 107.23M | - | - | - |
| Total current liabilities | 293.78M | 387.93M | 651.43M | 673.23M | 399.46M |
| Current deferred revenue | - | - | 1.14M | 0.92M | 175.80M |
| Net debt | 933.83M | - | 1327.04M | 1333.85M | 645.22M |
| Short term debt | 67.25M | 0.00M | 93.19M | 111.06M | 29.62M |
| Short long term debt | 35.73M | - | - | - | - |
| Short long term debt total | 1035.22M | - | 1448.11M | 1554.95M | 1023.32M |
| Other stockholder equity | 2341.13M | -20.08M | 2905.23M | 2923.78M | 76.55M |
| Property plant equipment | - | 768.11M | - | - | - |
| Total current assets | 447.81M | 429.68M | 551.97M | 884.00M | 917.83M |
| Long term investments | 0.26M | - | - | - | - |
| Net receivables | 80.82M | 61.27M | 82.65M | 61.22M | 79.25M |
| Long term debt | 512.92M | 466.90M | - | - | - |
| Inventory | 225.02M | 220.65M | 284.70M | 318.12M | 313.45M |
| Accounts payable | 74.59M | - | 104.59M | 109.47M | 33.79M |
| Accumulated other comprehensive income | -1.80M | - | -15.66M | -25.19M | -317.01M |
| Non currrent assets other | 13.55M | - | 589.76M | 673.50M | 489.09M |
| Non current assets total | 2392.33M | - | 3531.18M | 3742.55M | 3004.34M |
| Capital lease obligations | 278.31M | - | - | - | - |
| Long term debt total | - | 819.27M | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -0.17M | - | - | - | - |
| Total cashflows from investing activities | -71.80M | -93.83M | - | - | - |
| Net borrowings | -34.16M | - | - | - | - |
| Total cash from financing activities | -74.78M | -54.24M | -96.07M | 54.41M | 457.79M |
| Net income | -251.44M | -216.22M | -310.18M | -336.50M | -258.19M |
| Change in cash | -10.91M | 15.41M | -100.03M | -157.00M | 284.40M |
| Begin period cash flow | 112.30M | 91.82M | 221.10M | 378.10M | 93.69M |
| End period cash flow | 101.39M | 107.23M | 121.07M | 221.10M | 378.10M |
| Total cash from operating activities | 140.35M | 162.57M | 101.58M | 60.41M | -73.07M |
| Depreciation | 219.82M | 250.16M | 286.02M | 215.64M | 167.45M |
| Other cashflows from investing activities | -6.00M | -3.76M | - | - | - |
| Change to inventory | -3.79M | 2.99M | 13.30M | -20.96M | -116.75M |
| Change to account receivables | 6.82M | 2.21M | 0.15M | -26.32M | -31.67M |
| Sale purchase of stock | - | 0.16M | - | - | - |
| Other cashflows from financing activities | -49.72M | -11.69M | -42.31M | -19.66M | -6.25M |
| Capital expenditures | 64.55M | 98.15M | 94.89M | 175.29M | 215.59M |
| Change in working capital | 122.49M | 103.69M | 46.08M | 85.98M | -69.95M |
| Stock based compensation | 35.74M | 25.70M | 20.01M | 28.02M | 39.48M |
| Other non cash items | 84.15M | 53.91M | 675.60M | 528.33M | 597.15M |
| Free cash flow | 75.80M | 64.42M | 6.69M | -114.88M | -288.65M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(CAD) |
Price
(CAD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CURA Curaleaf Holdings Inc. |
-0.74 5.20% |
13.49 | - | 138.89 | 2.57 | 3.14 | 2.47 | 13.10 |
| BHC Bausch Health Companies Inc |
0.31 2.72% |
11.72 | 13.98 | 1.35 | 0.28 | 18.74 | 2.12 | 6.84 |
| CRON Cronos Group Inc |
0.16 3.36% |
4.92 | - | 32.15 | 9.80 | 0.95 | 1.47 | 1.90 |
| TLRY Tilray Inc |
0.41 11.02% |
4.13 | - | 1000.00 | 1.28 | 0.53 | 1.08 | -2.30 |
| GUD Knight Therapeutics Inc. |
0.02 0.18% |
11.28 | - | 48.54 | 1.64 | 0.96 | 1.60 | 11.97 |
Curaleaf Holdings, Inc. engages in the retail and wholesale of cannabis products in the United States and internationally. The company operates licensed cultivation; and pharma-grade cannabis processing and manufacturing facilities. It also supplies cannabis on a wholesale basis to Australia, New Zealand, the United Kingdom and various European countries, including Germany, Italy, Poland, the Czech Republic, Switzerland, Sweden and Norway. In addition, the company operates a medical cannabis clinic and holds a pharmacy license. It serves the medical and adult-use cannabis markets through retail and wholesale channels. The company is based in Stamford, Connecticut.
| Name | Title | Year Born |
|---|---|---|
| Mr. Boris Alexis Jordan | CEO & Chairman | 1966 |
| Mr. Joseph F. Lusardi | Executive Vice-Chairman | 1975 |
| Mr. Edward Kremer | Chief Financial Officer | 1972 |
| Mr. Peter Laurence Clateman J.D. | Chief Legal Officer | 1968 |
| Mr. Matthew S. Darin | Special Advisor | NA |
| Mr. Camilo Russi Lyon | Chief Investment Officer | NA |
| Ms. Christine Taylor | Chief Accounting Officer | NA |
| Mr. Jakob Feinstein | Manager of Investor Relations | NA |
| Mr. James S. Shorris | Chief Compliance Officer | 1961 |
| Ms. Kate Lynch | Executive Vice President of Marketing | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.